New psychosis treatment targets genetic mutation instead of symptoms

A novel treatment that targets the biological effects of a specific genetic mutation could help alleviate the symptoms of psychosis, a new study finds.

Deborah L. Levy, Ph.D. — from the McLean Hospital in Belmont, MA — led the new study, the findings of which now appear in the journal Biological Psychiatry.

It revealed that people who had additional copies of a certain gene, instead of the regular two, benefited from the treatment.

The mutation, called a copy number variant (CNV), affects the glycine decarboxylase gene.

Full story at Medical News Today

Published by

Will Savage

Quantum Units Continuing Education provides online CEU training's to licensed professional mental health therapists, counselors, social workers and nurses. Our blog provides updates in the field of news and research related to mental health and substance abuse treatment.